Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | KHK | P50053 | 2/20 | 0.54 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ULK1 | O75385 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGAV | P06756 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12295117 | 1.00 | NPSR1 (0.63) | NPSR1NPC1RAB9AKHKPSMB8 | |
| SCHEMBL31122583 | 1.00 | NPSR1 (0.63) | NPSR1NPC1RAB9AKHKPSMB8 | |
| SCHEMBL29697282 | 1.00 | NPSR1 (0.63) | NPSR1NPC1RAB9AKHKPSMB8 | |
| SCHEMBL17676960 | 1.00 | NPSR1 (0.63) | NPSR1NPC1RAB9AKHKPSMB8 | |
| SCHEMBL259395 | 0.96 | NPSR1 (0.66) | NPSR1NPC1RAB9AKHKPSMB8 | |
| SCHEMBL18591277 | 0.93 | NPSR1 (0.64) | NPSR1NPC1RAB9AKHKALDH1A1 | |
| SCHEMBL10326796 | 0.85 | LMNA (0.59) | NPSR1KHKPSMB8SCN9ALMNA | |
| SCHEMBL10327137 | 0.85 | LMNA (0.59) | NPSR1KHKPSMB8SCN9ALMNA | |
| SCHEMBL10106568 | 0.85 | LMNA (0.59) | NPSR1KHKPSMB8SCN9ALMNA | |
| SCHEMBL13976886 | 0.84 | PSMB8 (0.54) | NPSR1NPC1KHKPSMB8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414328-B1 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO SA (CH) | 2021-05-26 | — | — | EP | disclosed |
| US-9006454-B2 | Dihydroorotate dehydrogenase inhibitors | MERCK SERONO S.A. (CH) | 2015-04-14 | — | — | US | disclosed |
| US-8217204-B2 | Catalyst for asymmetric hydrogenation | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-12-23 | — | — | US | disclosed |
| WO-2010140636-A1 | ASYMMETRIC HYDROGENATION CATALYST | 高砂香料工業株式会社 (JP) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010115736-A2 | DIHYDROOROTATE DEHYDROGENASE INHIBITORS | MERCK SERONO S.A. (CH) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | H1-0, H1-5, ADH5 | NPSR1 2526/4885NPC1 2005/4885RAB9A 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.